TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04712422

Intervention type: OTHER
Intervention: Healthy subjects
Description: Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.

Intervention type: OTHER
Intervention: Pathologic group
Description: Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt.
Study: NCT03602326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy-Bobath group
Description: Neurodevelopmental Therapy-Bobath (NDT-B) is one of the most commonly used models for therapeutic management and treatment in patients with stroke. The basic philosophy underlying this approach is that; lesions in the central nervous system cause impairments in the coordination of movement and posture combined with problems in muscle tone which lead directly to functional limitations. According to the NDT-B approach, practice has a great role in treatment due to the fact that more practice leads to better motor learning and increases neural plasticity. According to NDT-B, the duration of treatment should not be limited to rehabilitation sessions, but should be designed to be implied throughout the day and should be adapted to the patients' daily life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart Rehabilitation Group (SR group)
Description: Standard Rehabilitation for Stroke consists of the hospitals' physiotherapy and rehabilitation routine.
Study: NCT02220868

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir, Ribavirin, and Stribild
Study: NCT00526968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 101
Description: 8 mg capsule, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 101
Description: 15 mg capsule, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule, single oral dose
Study: NCT03072680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS PAST
Description: Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS FUT
Description: Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS FUT
Description: Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DAILY ACTIVITIES
Description: Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app.
Study: NCT05754047

Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemistry (IHC) and in situ hybridization (ISH) Test
Description: These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors

Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemistry (IHC) and in situ hybridization (ISH) Test
Description: These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors

Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemistry (IHC) and in situ hybridization (ISH) Test
Description: These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
Study: NCT00569062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553X
Description: GW856553X 7.5mg BID for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GW856553X
Study: NCT00620490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Ropivacaine 0.5% 0.1 ml/kg per hour

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nacl 0,9%
Description: saline 0.9% 0.1 ml/kg per hour
Study: NCT00688064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene BPO Gel associated with Doxycyline Hyclate
Description: Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Gel associated with Doxycycline Hyclate
Description: Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
Study: NCT04374084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion plus Cupping
Description: Moxibustion: The burning of a small, thimble sized, smoldering plug of dried leaves on the skin at an acupuncture point. Usually the plugs contain leaves of mugwort or moxa. Cupping takes the pot as a tool, uses the combustion to remove the air in the pot, causes a negative pressure, and makes it adsorb on the skin of the acupoints. UseBaixiaojiumoxibustion on each acupoint for 10-15 minutes, the temperature of moxibustion should be adjusted within patient's tolerance level. Use diameter of 5-6 cm acuum cupper to cupping on each acupoint for 5-8 minutes.
Study: NCT04048148

Intervention type: DEVICE
Group type: OTHER
Intervention: Novel designed myopia control spectacle lenses
Description: A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.

Intervention type: DEVICE
Group type: OTHER
Intervention: Novel designed myopia control spectacle lenses
Description: A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
Study: NCT02115646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractionated carbon dioxide laser
Description: patients will have serial laser treatments
Study: NCT01051232

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active
Description: Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects will receive the placebo under fasting condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active
Description: Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects will receive the placebo under fasting condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active
Description: Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects will receive the placebo under fasting condition.
Study: NCT00575406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: i.v., 375 mg/m2, d0 or d1 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: i.v., 375 mg/m2, d0 or d1 of each treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: i.v., 750 mg/m2, d1 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: i.v., 750 mg/m2, d1 of each treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: i.v., 50 mg/m2, d1 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal Doxorubicin
Description: i.v., 50 mg/m2, d1 of each treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristin
Description: i.v., 2mg, d1 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: i.v., 2mg, d1 of each treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: p.o., 100mg, d1 - d5 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: p.o., 100mg, d1 - d5 of each treatment cycle
Study: NCT04071444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin program
Description: The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
Study: NCT02524223

Intervention type: OTHER
Group type: OTHER
Intervention: Systematic HPV DNA assay in semen and cervicovaginal scrape
Description: Screening of HPV status at the genital level of males enrolled in MAP program.

Intervention type: OTHER
Group type: OTHER
Intervention: Systematic HPV DNA cervicovaginal scrape
Description: Screening of HPV status at the genital level of females enrolled in MAP program.

Intervention type: OTHER
Group type: OTHER
Intervention: systematic HPV Status in newborns in case of pregnancy
Study: NCT01390363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Only Phone Call
Description: A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent and Adolescent Phone Call
Description: A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
Study: NCT02623088

Intervention type: OTHER
Intervention: PAP Therapies (CPAP)
Description: Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
Study: NCT02285140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: administration as outlined
Study: NCT05680350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Exploration
Description: Laparoscopic Exploration to diagnose \& grade endometriosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Exploration
Description: Laparoscopic Exploration to diagnose \& grade endometriosis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Estimation of Plasma Expression level of MICRO RNA 203 & 210
Description: estimation of Plasma Expression level for GeneMicro RNA 203 \& 210 by qRT-PCR
Study: NCT02083315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130 1.5 mg
Description: TRV130 1.5 mg IV x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130 3 mg
Description: TRV130 3 mg IV x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130 4.5 mg
Description: TRV130 4.5 mg IV x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10 mg
Description: Morphine 10 mg IV x 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water IV x 1 dose
Study: NCT01195714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
Study: NCT04035642

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 24 Gy Single dose
Description: Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)
Description: Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal balloon with air filling
Description: A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urethral catheter loaded with beacon transponders
Description: A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
Study: NCT03151018

Intervention type: DEVICE
Intervention: Resolute Onyx
Study: NCT01652365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RDT Training and Subsidy Offered

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RDT Training and Subsidy Offered

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information/Education Campaign

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information/Education Campaign
Study: NCT03432013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CUD-AMT
Description: Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SUD-CBT
Description: Participants will receive traditional cognitive behavioral therapy for substance use disorder
Study: NCT06348693

Intervention type: OTHER
Intervention: cell isolation from tumor biopsies and biomarker investigation
Description: cellular and molecular analysis on cancer stem cells and endothelial cells from tumor biopsies and investigation of tissue and systemic biomarkers
Study: NCT01610466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic bariatric surgery ex-vivo training curriculum
Description: The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
Study: NCT03976713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Yishen granule
Description: Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bufei Yishen granule
Description: Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Powder for Inhalation
Description: Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium Bromide Powder for Inhalation
Description: Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
Study: NCT01834963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa、Fluorouracil
Description: Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin、Fluorouracil
Description: Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks
Study: NCT02208726

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose pillules
Description: Unmedicated sucrose pillules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic homaccord
Description: Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
Study: NCT03190577

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample
Description: two 5 ML EDTA tubes of blood will be collected once by patient
Study: NCT00758849

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fipamezole
Description: One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
Study: NCT00858910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) training
Description: MI training encloses the internal rehearsal of a known motor skill without any overt motor output.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) training
Description: MI training encloses the internal rehearsal of a known motor skill without any overt motor output.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control intervention
Description: The control intervention encloses relaxation and breathing exercises, and information about:~* the disease (stroke),~* therapy options,~* self-help groups and their offers for support,~* helping aids for independent living at home.
Study: NCT03909659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction
Description: A supply of a reduced-sodium added-potassium salt substitute
Study: NCT05063409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
Study: NCT04188821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast drain removal
Description: Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast drain removal
Description: Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care.
Study: NCT00376948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride